Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review
Sign Up to like & getrecommendations! Published in 2020 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001198
Abstract: Background/objective Data regarding the nephrotoxicity of the peptide receptor radionuclide therapy (PRRT) with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs (RSA) are inconclusive. We aimed to evaluate the short- and long-term nephrotoxicity following PRRT usage in patients… read more here.
Keywords: therapy; radiolabeled somatostatin; nephrotoxicity; somatostatin analogs ... See more keywords
Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14051172
Abstract: Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology because these proteins are overexpressed on the cell membranes of different human malignancies, especially neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs). Radiolabeled short peptide… read more here.
Keywords: radiolabeled somatostatin; sst; new developments; somatostatin analogs ... See more keywords